Project Grant R01AI184581
Award Date
8/16/24
Completion Date
7/31/29
Dollars Obligated
$1M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
San Antonio, TX 78227, USA
Similar Awards
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate the sirtuin-dependent regulation of tuberculosis (TB) and HIV interactions in macrophages. The total award amount is $1,297,775.00 over a 5-year period from August 1, 2024 to July 31, 2029. The primary objectives are to: 1) analyze the impact of early TB and HIV infection on sirtuin gene and protein...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant valued at $718,758 to the Texas Biomedical Research Institute under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant is focused on evaluating the use of IL-21-IgFc fusion protein as a host-directed immunotherapy to improve immune reconstitution and reduce the risk of latent tuberculosis (TB) reactivation in Mycobacterium tuberculosis (MTB) and simian immunodeficiency virus (SIV)...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to evaluate the safety, immunogenicity, and efficacy of an attenuated Mycobacterium tuberculosis (MTB) vaccine candidate in the setting of HIV co-infection. The $905,998 award to the Texas Biomedical Research Institute aims to directly test the hypothesis that the SIGH-based attenuated MTB vaccine...
This $737,342 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development and validation of advanced imaging technologies to improve the detection and study of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The key objectives are to: 1) Develop new imaging technologies capable of detecting single MTB bacteria in vitro and in vivo; 2) Use...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $447,009 to the University of Massachusetts to conduct research on the early immune response to Mycobacterium tuberculosis (MTB) infection. The key objectives are to: 1) Categorize alveolar macrophage sensing abilities and defects in responding to MTB pathogen-associated molecular patterns, and screen for novel...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $749,414 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University for research on the role of macrophage drug efflux pump MDR1 in Mycobacterium tuberculosis (M.TB) pathogenesis. The primary objectives are to: 1) define the role of MDR1 in M.TB survival in macrophages; 2) determine if HSF1 activation or MDR1 inhibition can shorten M.TB sterilization by TB drugs;...
This $246,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research supports research to investigate the role of lung repair and regeneration pathways in tuberculosis (TB). The award aims to determine the functional role of the bone morphogenetic protein (BMP) signaling pathway in TB control and reactivation, as well as characterize the cellular mechanisms of BMP pathway activation during TB...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to characterize the burden, severity, and phenotypic presentation of post-tuberculosis (TB) lung disease (PTLD) and its association with interleukin-6 (IL-6) signaling pathways in TB patients with and without HIV. The total funding amount is $743,698.00 over the award period from Sep 20, 2024 to Aug 31, 2029. The grant will leverage an...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $711,993 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Boston Medical Center Corporation (BMC) on June 11, 2025. The grant supports research to understand the effects of Mycobacterium tuberculosis (MTB) disease on HIV-1 pathogenesis, immunity, and persistence in people living with HIV. Specifically, the project will assess how MTB disease impacts the HIV-1 immune response,...
This Project Grant award, valued at $749,192.00 and awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to better understand the molecular basis for differences in efficacy between different sub-strains of the Bacillus Calmette-Guérin (BCG) vaccine used to prevent tuberculosis (TB). The award will fund two key efforts: 1) Comparing animal model biomarkers of BCG sub-strain...